Can Fite BioPharma Ltd (CANF)

[Spideyboy]

Just listened to the webcast.

As expected the data from this trial is actually better than made out to be due to the precise end-points chosen.

However there is on thing very puzzling.

The ALT data on slide 10: The slide shows the non-significant difference values of p=0.066 and p=0.079, while the KOL said that when he did the t-test for this, he arrived at significant differences for both these graphs at p=0.04 and p=0.045.

How could the analysis come up with such varying results, and of which would have had a completely different impact on the value of the results to the stock-price.

Additionally the error bars are quite wide, which I think may cause the difference in p-values, but that will be mainly down to the small size of the trial, 20 patients in each group. A higher sample should minimise the impact of the error bars and provide closer to the apparent significant difference. Again trial size has scuppered the results! Oi Vey!

Still bullish on CANF in the long run, RA and Psoriasis data out end of year, that'll be make or break time. At least those are large sample, hope they are long enough too!